Allos AI applies Causal AI to model how formulation, dosing, delivery, and patient biology interact, allowing pharmaceutical partners to redesign existing complex generics and next-generation small-molecule drugs for chronic diseases. Its platform leverages real-world evidence to reduce development uncertainty, shorten clinical timelines, and create more predictable paths to regulatory approval. By turning drug reformulation into a data-driven engineering discipline, Allos aims to revive long-stalled development pathways and unlock stalled programs. The company’s transparent, or “glass-box,” models enable smaller and more interpretable clinical studies that accommodate patient heterogeneity upfront. Funding will be used to expand formulation development and data-science teams while focusing on hard-to-genericize medicines. Allos collaborates with pharmaceutical companies to modernize legacy assets and expand access to complex generics. Headquartered in Oxford, United Kingdom, the AI-native company was founded by an Oxford-trained quantum physicist, applied AI researchers, and veterans of complex generics.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026